In this case they are best used during the recovery
phase after chemotherapy is completed.
Not exact matches
Treating patients with high - dose radiotherapy
after chemotherapy and surgery for malignant pleural mesothelioma does not achieve improvements in local relapse and overall survival, according to data from a prospective randomized
phase II trial presented at ESMO 2014 Congress in Madrid.
A
Phase 3 Open - Label Randomized Study of Quizartinib (AC220) Monotherapy Versus Salvage
Chemotherapy in Subjects with FLT3 - ITD Positive Acute Myeloid Leukemia (AML) Refractory To or Relapsed
After First - line Treatment With or Without Hematopoietic Stem Cell Transplantation (HSCT) Consolidation
A Randomized,
Phase III Trial to Evaluate The Efficacy and Safety of MK - 3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor - Negative Breast Cancer with ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (yPN +)
After Neoadjuvant
Chemotherapy
A Randomized, Double - Blinded,
Phase II Study of Maintenance Pembrolizumab versus Placebo
after First - line
Chemotherapy in Patients with Metastatic Urothelial Cancer
Investigators led by Edward S. Kim, MD, of MD Anderson Cancer Center in Houston, initiated the SELECT trial
after earlier,
phase II studies showed that cetuximab improved response rates when added to
chemotherapy regimens for patients with recurrent or progressive NSCLC.
[iv] Nivolumab versus
chemotherapy in patients with advanced melanoma who progressed
after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open - label,
phase 3 trial.